Dr Nicky Willis

Nicky started his career in medicinal chemistry in 2013 at the Novartis Institute for Biomedical Research investigating novel anti-inflammatory agents. In 2015, Nicky joined Prof. Angela Russell’s group at the University of Oxford, supporting the development of Summit Therapeutics’ Duchenne Muscular Dystrophy (DMD) clinical candidate Ezutromid and fast follower compounds. In 2017, he moved to the UCL, Alzheimer’s Research UK, Drug Discovery Institute, where he has lead a number of medical chemistry teams. Nicky also has a background in early-stage process chemistry from appointments at Piramal Healthcare and GlaxoSmithKline.